利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

7 条记录 (耗时 0.022 秒)

    Controlling attention and memory by altering neuronal carbonic anhydrase activity
    2.
    发明授权
    Controlling attention and memory by altering neuronal carbonic anhydrase activity 失效

    公开(公告)号：US06552053B2

    公开(公告)日：2003-04-22

    申请号：US09875283

    申请日：2001-06-07

    申请人： Miao-Kun Sun ,  Daniel L. Alkon ,  Wei-Qin Zhao

    发明人： Miao-Kun Sun ,  Daniel L. Alkon ,  Wei-Qin Zhao

    IPC分类号： A61K3141

    CPC分类号： A61K31/00 ,  A61K31/433

    摘要： The invention provides a method for modulating attentive cognition comprising administering a compound that alters intraneuronal carbonic anhydrase activity thereby affecting establishment of a theta rhythm. The metabolic pathway of the compound preferably involves bicarbonate-mediated GABAergic depolarization. The term “attentive cognition” is meant to encompass memory formation, learning, spatial memory, and attention. The modulating may be stimulating, or the compound may have the multiple effects of inhibiting intraneuronal carbonic anhydrase activity, establishment of a theta rhythm, and memory acquisition. The invention further provides a method of modulating memory and attention comprising switching theta rhythm on and off, the switching comprising potentiating or inhibiting intraneuronal carbonic anhydrase activity.

    Synergistic enhancement of cognitive ability
    4.
    发明授权
    Synergistic enhancement of cognitive ability 有权
    协同增强认知能力

    公开(公告)号：US06821979B2

    公开(公告)日：2004-11-23

    申请号：US10172005

    申请日：2002-06-17

    申请人： Daniel L. Alkon ,  Miao-Kun Sun

    发明人： Daniel L. Alkon ,  Miao-Kun Sun

    IPC分类号： A61K3152

    CPC分类号： A61K31/417 ,  A61K31/135 ,  A61K31/198 ,  A61K31/4172 ,  A61K31/52 ,  A61K2300/00

    摘要： The present invention relates to the combination of a methylxanthine and a carbonic anhydrase activator to provide synergistic effects. The invention further relates to the improved/enhanced cognitive ability of individuals, particularly those suffering from various disorders, such as Alzheimer's Disease, stroke, hypoxia, general dementia, ADHD, mental retardation, and “sun down” syndrome.

    摘要翻译： 本发明涉及甲基黄嘌呤和碳酸酐酶活化剂的组合以提供协同效应。 本发明还涉及个体，特别是患有诸如阿尔茨海默氏病，中风，缺氧，一般性痴呆，ADHD，智力低下和“下垂”综合症等各种疾病的个体的改善/增强的认知能力。

    THERAPEUTIC EFFECTS OF BRYOSTATINS, BRYOLOGS, AND OTHER RELATED SUBSTANCES ON ISCHEMIA/STROKE-INDUCED MEMORY IMPAIRMENT AND BRAIN INJURY
    5.
    发明申请
    THERAPEUTIC EFFECTS OF BRYOSTATINS, BRYOLOGS, AND OTHER RELATED SUBSTANCES ON ISCHEMIA/STROKE-INDUCED MEMORY IMPAIRMENT AND BRAIN INJURY 审中-公开
    BRYOSTATINS，BRYOSS，和其他相关物质对异位/诱导性记忆损伤和脑损伤的治疗效果

    公开(公告)号：US20130165453A1

    公开(公告)日：2013-06-27

    申请号：US13553565

    申请日：2012-07-19

    申请人： Miao-Kun Sun ,  Daniel L. Alkon

    发明人： Miao-Kun Sun ,  Daniel L. Alkon

    IPC分类号： A61K31/365 ,  A61K31/194

    CPC分类号： A61K31/05 ,  A61K31/00 ,  A61K31/335 ,  A61K31/35 ,  A61K31/365 ,  A61K31/395 ,  A61K31/4015 ,  A61K38/00 ,  A61K38/1825

    摘要： The invention provides for the use of protein kinase activators or boosters of nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF) or other neurotrophic factors to treat stroke. Specifically, the present invention provides methods of treating stroke comprising the steps of identifying a subject having suffered a stroke and administering to said subject an amount of a pharmaceutical composition comprising a protein kinase C (PKC) activator or 4-methylcatechol acetic acid (MCBA) and a pharmaceutically acceptable carrier effective to treat at least one symptom of stroke.

    摘要翻译： 本发明提供了使用蛋白激酶激活剂或神经生长因子（NGF）的促进剂，脑源性神经营养因子（BDNF）或其他神经营养因子来治疗中风。 具体地说，本发明提供治疗中风的方法，其包括以下步骤：鉴定遭受中风的个体，并向所述受试者施用一定量的包含蛋白激酶C（PKC）激活剂或4-甲基儿茶酚乙酸（MCBA）的药物组合物， 和有效治疗中风的至少一种症状的药学上可接受的载体。